Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy

Current Drug Targets - Cardiovascular and Haematological Disorders

Volumn 5, Issue 4, 2005, Pages 337-343

  Barbaro, G ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE   (Italy)

Author keywords

Cardiovascular disease; Highly active antiretroviral therapy; Human immunodeficiency virus; Metabolic syndrome

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIPARASITIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATAZANAVIR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DELAVIRDINE; DIPYRIDAMOLE; EFAVIRENZ; FOSCARNET; GANCICLOVIR; INDINAVIR; NELFINAVIR; NEVIRAPINE; PENTAMIDINE; PROTEINASE INHIBITOR; QUINIDINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STEROID; TENOFOVIR DISOPROXIL; UNINDEXED DRUG; WARFARIN; ZIDOVUDINE;

ANGIONEUROTIC EDEMA; ATHEROSCLEROSIS; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONGESTIVE CARDIOMYOPATHY; DRUG FATALITY; DYSLIPIDEMIA; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE TACHYCARDIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOKALEMIA; HYPOTENSION; INSULIN RESISTANCE; KIDNEY FAILURE; LACTIC ACIDOSIS; METABOLIC SYNDROME X; MYOCARDITIS; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPPORTUNISTIC INFECTION; ORTHOSTATIC HYPOTENSION; QT PROLONGATION; REVIEW; SIDE EFFECT; SUDDEN DEATH; THROMBOPHLEBITIS; TORSADE DES POINTES;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; RISK FACTORS;

EID: 23744491679     PISSN: 15680061     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568006054553444     Document Type: Review

References (61)

1. Barbarini, G., Barbaro, G. Incidence of the involvement of the cardiovascular system in HIV infection. AIDS, 2003, 17 (S1), S46-S50.
2. Pugliese, A., Isnardi, D., Saini, A., Scarabelli, T., Raddino, R., Torre, D. Impact of higly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J. Infect., 2000, 40, 282-284.
3. Bijl, M., Dieleman, J.P., Simoons, M., Van Der Ende, M.E. Low prevalence of cardiac abnormalities in an HIV-seropositive population on antiretroviral combination therapy. J. AIDS, 2001, 27, 318-320.
4. Nzuobontane, D., Blackett, K.N., Kuaban, C. Cardiac involvement in HIV-infected people in Yaounde,Cameroon. Postgrad Med. J., 2002, 78, 678-681.
5. Heidenreich, P.A., Eisenberg, M.J., Kee, L.L., Somelofski, C.A., Hollander, H., Schiller, N.B., Cheitlin, M.D. Pericardial effusion in AIDS. Incidence and survival. Circulation, 1995, 92, 3229-3234.
6. Barbaro, G., Di Lorenzo, G., Grisorio, B., Barbarini, G. and the Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS investigators. Cardiac involvement in the acquired immunodeficiency syndrome. A multicenter clinical-pathological study. AIDS Res. Hum. Retroviruses, 1998, 14, 1071-1077.
7. Dal Maso, L., Serraino, D., Franceschi, S. Epidemiology of HIV-associated malignancies. Cancer Treat Res., 2001, 104, 1-18.
8. Barbaro, G. Reviewing the clinical aspects of HIV-associated pulmonary hypertension. J. Respir. Dis., 2004, 25, 289-293.
9. Deyton, L., Walker, R., Kovacs, J., Herpin, B., Parker, M., Masur, H., Fauci, A.S., Lane, H. Reversible cardiac dysfunction associated with interferon alpha therapy in AIDS patients with Kaposi's sarcoma. N. Engl. J. Med., 1989, 321, 1246-1249.
10. Barbaro, G., Fisher, S.D., Lipshultz, S.E. Pathogenesis of HIV-associated cardiovascular complications. Lancet Infectious Disease, 2001, 1, 115-124.
11. Arsura, E.L., Ismail, Y., Freeman, S., Karunakav, A.R. Amphotericin B-induced dilated cardiomyopathy. Am. J. Med., 1994, 97, 560-562.
12. Cohen, A.J., Weiser, B., Afzal, Q., Fuhrer, J. Ventricular tachycardia in two patients with AIDS receiving ganciclovir (DHPG). AIDS, 1990, 4, 807-809.
13. Lopez, J.A., Harold, J.G., Rosenthal, M.C., Oseran, D.S., Schapira, J.N., Peter, T. QT prolungation and torsade de pointes after administration of thrimethoprim-sulfamethoxazole. Am. J. Cardiol., 1987, 59, 376-377.
14. Stein, K.M., Haronian, H., Mensah, G.A., Acosta, A., Jacobs, J., Klingfield, P. Ventricular tachycardia and torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Am. J. Cardiol., 1990, 66, 888-889.
15. Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D.J., Cooper, D.A. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 1998, 12, F51-F58.
16. Grinspoon, S., Carr, A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med., 2005, 352, 48-62.
17. Garg, A. Acquired and inherited lipodystrophies. N Engl J Med 2005, 350, 1220-1234.
18. Carr, A. HIV lipodystrophy: risk factors,pathogenesis, diagnosis and management. AIDS, 2003, 17 (S1), S141-S148.
19. Carr, A., Hudson, J., Chuan, J., Mallal, S., Law, M., Hoj, J., Doong, N., French, M., Smith, D., Cooper, D.A. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS, 2001, 15, 1811-1822.
20. Clumeck, N., Goebel, F., Rozenbaum, W., Gerstoft, J., Staszewski, S., Montaner, J., Johnson, M., Gazzard, B.G., Stone, C., Athisegaran, R., Moore, S. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS, 2001, 15, 1517-1526.
21. Ruiz, L., Negredo, E., Domingo, P., Paredes, R., Francia, E., Balague, M., Gel, S., Bonjoch, A., Fumaz, C.R., Johnston, S., Romeu, J., Lange, J., Clotet, B. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J. AIDS, 2001, 27, 229-236.
22. Executive summary of the Third Report of the National Cholesterol Education program (NCEP).Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 2001, 285, 2486-2497.
23. Guidelines for the Evaluation and Management of Dyslipidemia inHuman Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretrovial Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trial Groups. Clin. Infect. Dis., 2004, 37, 613-627.
24. Volberding, P., Murphy, R., Barbaro, G., Barbarini, G., Bruno, R., Cirelli, A., Currie, P., Di Lorenzo, G., Fantoni, M., Filice, G., Galli, M., Grisorio, B., Moroni, M., Recusani, F., Sacchi, P., Scevola, D., Torre, D., Vittecoq, D. The Pavia Consensus Statement. AIDS, 2003, 17 (S1), S170-S179.
25. van der Valk, M., Kastelein, J.J.P., Murphy, R.L., van Leth, F., Katlama, C., Horban, A., Glesby, M., Behrens, G., Clotet, B., Stellato, R.K., Molhuizen, H.O.F., Reiss, P. on behalf of the Atlantic Study Team. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS, 2001, 15, 2407-2414.
26. Hadigan, C., Yawetz, S., Thomas, A., Havers, F., Sax, P.E., Grinspoon, S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann. Intern. Med., 2004, 140, 786-794.
27. Carr, A., Workman, C., Carey, D., Rogers, G., Martin, A., Baker, D., Wand, H., Law, M., Samaras, K., Emery, S., Cooper, D.A., Rosey investigators. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet, 2004, 363, 429-438.
28. Aoun, S., Ramos, E. Hypertension in the HIV-infected patient. Curr. Hypertens. Rep., 2000, 2, 478-481.
29. Sattler, F.R., Qian, D., Louie, S., Johnson, D., Briggs, W., DeQuattro, V., Dube, M.P. Elevated blood pressure in subjects with lipodystrophy. AIDS, 2001, 15, 2001-2010.
30. Carr, A., Samaras, K., Chisholm, D.J., Cooper, D.A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet, 1998, 351, 1881-1883.
31. Mooser, V., Carr, A. Antiretroviral therapy-associated hyperlipidemia in HIV disease. Curr. Opin. Lipidol., 2001, 12, 313-319.
32. Fauvel, J., Bonnet, E., Ruidavets, J.B., Ferrièes, J., Toffoletti, A., Massip, P., Chap, H., Perret, B. An interaction between apo C-III variants and protease inhibitors contributes to high tiglyceride/low HDL levels in treated HIV patients. AIDS, 2001, 15, 2397-2406.
33. Caron, M., Auclair, M., Sterlingot, H., Kornprobst, M., Capeau, J. Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS, 2003, 17, 2437-2444.
34. Caron, M., Auclair, M., Lagathu, C., Lombes, A., Walker, U., Kornprobst, M., Capeau, J. The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS, 2004, 18, 2127-2136.
35. McComsey, G.A., Paulsen, D., Lonergan, J.T., Hessenthaler, S.M., Hoppel, C.L., Williams, V.C., Fisher, R.L., Cherry, C.L., White-Owen, C., Thompson, K.A., Ross, S.T., Hernandez, J.E., Ross, L.L. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS, 2005, 19, 15-23.
36. Behrens, G.M., Lloyd, D., Schmidt, H.H., Schmidt, R.E., Trembath, R.C. Lessons from lipodystrophy: LMNA, encoding lamin A/C, in HIV therapy- associated lipodystrophy. AIDSi, 2000, 14, 1854-1855.
37. Mynarcik, D.C., McNurlan, M.A., Steigbigel, R.T., Fuhrer, J., Gelato, M.C. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J. Acquir. Immune. Defic. Syndr., 2000, 25, 312-321.
38. Gougeon, M.L., Penicaud, L., Fromenty, B., Leclercq, P., Viard, J.P., Capeau, J. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir. Ther., 2004, 9, 161-177.
39. Vigouroux, C., Maachi, M., Nguyen, T.H., Coussieu, C., Gharakhanian, S., Funahashi, T., Matsuzawa, Y., Shimomura, I., Rozenbaum, W., Capeau, J., Bastard, J.P. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS, 2003, 17, 1503-1511.
40. Haque, W.A., Shimomura, I., Matsuzawa, Y., Garg, A. Serum adiponectin and leptin levels in patients with lipodystrophies. J. Clin. Endocrinol. Metab., 2002, 87, 2395-2398.
41. Addy, C.L., Gavrila, A., Tsiodras, S., Brodovicz, B., Karchmer, A.W., Mantzoros, C.S. Hypoadiponectinemia is associated with insulin resistance,hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J. Clin. Endocrinol. Metab., 2003, 88, 627-636.
42. Kosmiski, L., Kuritzkes, D., Lichtenstein, K., Eckel, R. Adipocyte-derived hormone levels in HIV lipodystrophy. Antivir. Ther., 2003, 8, 9-15.
43. Murata, H,. Hruz, P.W., Mueckler, M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J. Biol. Chem., 2000, 275, 20251-20254.
44. Fiala, M., Murphy, T., MacDougall, J., Yang, W., Luque, A., Iruela-Arispe, L., Cashman, J., Buga, G., Byrns, R.E., Barbaro, G., Arthos, J. HAART drugs induce mitochondrial damage and intracellular gaps and gp120 causes apoptosis. Cardiovasc. Toxicol., 2004, 4, 327-338.
45. Fiala, M., Popik, W., Qiao, J-H., Lossinsky, A.S., Alce, T., Tran, K., Yang, W., Roos, K.P., Arthos, J. HIV-1 Induces Cardiomyopathy by cardiomyocyte invasion and gp120,Tat, and cytokine apoptotic signaling. Cardiovasc. Toxicol., 2004, 4, 97-107.
46. Stein, J.H., Klein, M.A., Bellehumeur, J.L., Mc Bride, P.E., Wiebe, D.A., Otvos, J.D., Sosman, J.M. Use of human immunodeficiency virus-1 protease inhbitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation, 2001, 104, 257-262.
47. Zhong, D.S., Lu, X.H., Conklin, B.S., Lin, P.H., Lumsden, A.B., Yao, Q., Chen, C. HIV protease ritonavir induces cytotoxicity of human endothelial cells. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 1560-1566.
48. Holmberg, S.D., Moorman, A.C., Williamson, J.M., Tong, T.C., Ward, D.J., Wood, K.C., Greenberg, A.E., Janssen, R.S. and the HIV Outpatient Study (HOPS) Investigators. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet, 2002, 360, 1747-1748.
49. Friis-Moller, N., Weber, R., Reiss, P., Thiebaut, R., Kirk, O., D'Arminio Monforte, A., Pradier, C., Morfeldt, L., Mateu, S., Law, M., El-Sadr, W., De Witt, S.., Sabin, C.A., Phillips, A.N., Lundgren, J.D. for the DA.D. Study Group. Cardiovascular risk factors in HIV patients-association with antiretroviral therapy. Results from DAD study. AIDS, 2003, 17, 1179-1193.
50. Bozzette, S.A., Ake, C.F., Tam, H.K., Chang, S.W., Louis, T.A. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N. Engl. J. Med., 2003, 348, 702-710.
51. Mary-Krause, M., Cotte, L., Simon, A., Partisani, M., Costagliola, D. and the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS, 2003, 17, 2479-2486.
52. Barbaro, G., Di Lorenzo, G., Cirelli, A., Grisorio, B., Lucchini, A., Hazra, C., Barbarini, G. An open-label,prospective,observational study of the incidence of coronary artery disease in patients with HIV receiving highly active antiretroviral therapy. Clin. Ther., 2003, 25, 2405-2418.
53. Depairon, M., Chessex, S., Sudre, P., Rodondi, N., Doser, N., Chave, J.P., Riesen, W., Nicod, P., Darioli, R., Telenti, A., Mooser, VwtSHCS. Premature atheroscleosis in HIV-infected individuals: focus on protease inhibitor therapy. AIDS, 2001, 15, 329-334.
54. Hsue, P.Y., Lo, J.C., Franklin, A., Bolger, A.F., Martin, J.N., Deeks, S.G., Waters, D.D. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation, 2004, 109, 1603-1608.
55. Maggi, P., Serio, G., Epifani, G., Fiorentino, G., Saracino, A., Fico, C., Perilli, F., Lillo, A., Ferraro, S., Gargiulo, M., Chirianni, A., Angarano, G., Regina, G., Pastore, G. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS, 2000, 14, F123-F128.
56. Witz, M., Lehmann, J., Korzets, Z. Acute brachial artery thrombosis as the initial manifestation of human immunodeficiency virus infection. Am. J. Hematol., 2000, 64, 137-139.
57. Hadigan, C., Meigs, J.B., Rabe, J., D'Agostino, R.B., Wilson, P.W., Lipinska, I., Tofler, G.H., Grinspoon, S.. Increased PAI-1 and tPA Antigen Levels Are Reduced with Metformin Therapy in HIV-Infected Patients with Fat Redistribution and Insulin Resistance. J. Clin. Endocrinol. Metab., 2001, 86, 939-943.
58. Nair, R., Robbs, J.V., Chetty, R., Naidoo, N.G., Woolgar, J. Occlusive arterial disease in HIV-infected patients: a preliminary report. Eur. J. Vasc. Endovasc. Surg., 2000, 20, 353-357.
59. Sullivan, P.S., Dworkin, M.S., Jones, J.L., Hooper, W.C. Epidemiology of thrombosis in HIV-infected individuals. The Adult/Adolescent Spectrum of HIV Disease Project. AIDS, 2000, 14, 321-324.
60. Miguez-Burbano, M.J., Burbano, X., Rodriguez, A., Lecusay, R., Rodriguez, N., Shor-Posner, G. Development of thrombocytosis in HIV+ drug users: impact of antiretroviral therapy. Platelets, 2002, 13, 183-185.
61. Barbaro, G. Cardiovascular manifestations of HIV infection. Circulation, 2002, 106, 1420-1425.